Rocuronium blocks the muscle nicotinic acetylcholine receptor, so Succinylcholine cannot act there — the effect of Succinylcholine is reduced or lost.
Succinylcholine is an agonist at the muscle nicotinic acetylcholine receptor: it binds and switches the receptor on. Rocuronium is an antagonist at the same site and switches nothing on. With both present they compete for the same pocket, and whichever is there in greater effective concentration decides what the receptor does.
Given together they work against whatever each was started for. If both are genuinely needed, expect less of Succinylcholine’s effect than its dose would suggest.
This is a pharmacodynamic interaction. Neither drug changes the other’s concentration, so a level, an AUC estimate or a genotype looks entirely normal while the clinical effect is blunted.
The direction can be the useful one. The same opposition is what makes a reversal agent, an antidote or a planned antagonist work.



The ring marks the peg each drug wears for this receptor — the same cross-illumination Interact! draws when the two are put side by side.

